{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T19:50:46Z","timestamp":1775591446074,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science Center","award":["2016\/23\/B\/NZ7\/01280"],"award-info":[{"award-number":["2016\/23\/B\/NZ7\/01280"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Preclinical and clinical studies have indicated that impaired endogenous synthesis of glutathione during early postnatal development plays a significant role in the pathophysiology of schizophrenia. Moreover, some studies have suggested that antidepressants are able to increase the activity of atypical antipsychotics which may efficiently improve the treatment of negative and cognitive symptoms of schizophrenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the present study, we investigated the influence of repeated co-treatment with escitalopram and aripiprazole on the schizophrenia-like behavior and BDNF mRNA expression in adult rats exposed to glutathione deficit during early postnatal development. Male pups between the postnatal days p5\u2013p16 were treated with the inhibitor of glutathione synthesis, BSO (L-buthionine-(S,R)-sulfoximine) and the dopamine uptake inhibitor, GBR 12,909 alone or in combination. Escitalopram and aripiprazole were given repeatedly for 21\u00a0days before the tests. On p90\u201392 rats were evaluated in the behavioral and biochemical tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>BSO given alone and together with GBR 12,909 induced deficits in the studied behavioral tests and decreased the expression of BDNF mRNA. Repeated aripiprazole administration at a higher dose reversed these behavioral deficits. Co-treatment with aripiprazole and an ineffective dose of escitalopram also abolished the behavioral deficits in the studied tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The obtained data indicated that the inhibition of glutathione synthesis in early postnatal development induced long-term deficits corresponding to schizophrenia-like behavior and decreased the BDNF mRNA expression in adult rats, and these behavioral deficits were reversed by repeated treatment with a higher dose of aripiprazole and also by co-treatment with aripiprazole and ineffective dose of escitalopram.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s43440-021-00318-z","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T14:03:41Z","timestamp":1629122621000},"page":"1712-1723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of repeated co-treatment with escitalopram and aripiprazole on the schizophrenia-like behaviors and BDNF mRNA expression in the adult Sprague\u2013Dawley rats exposed to glutathione deficit during early postnatal development of the brain"],"prefix":"10.1007","volume":"73","author":[{"given":"Marta A.","family":"Lech","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Kami\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Le\u015bkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Lorenc-Koci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8538-3594","authenticated-orcid":false,"given":"Zofia","family":"Rog\u00f3\u017c","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"318_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0896-6273(00)00111-2","volume":"28","author":"DA Lewis","year":"2000","unstructured":"Lewis DA, Lieberman JA. Caching up on schizophrenia: natural history and neurobiology. Neuron. 2000;28:325\u201334.","journal-title":"Neuron"},{"key":"318_CR2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1177\/070674370204700904","volume":"47","author":"EM Goldner","year":"2002","unstructured":"Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry. 2002;47:833\u201343.","journal-title":"Can J Psychiatry"},{"key":"318_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/sj.mp.4001563","volume":"10","author":"CA Tamminga","year":"2005","unstructured":"Tamminga CA, Holcomb HH. Phenotype of schizophrenia: a review and formulation. Mol Psychiatry. 2005;10:27\u201339.","journal-title":"Mol Psychiatry"},{"key":"318_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.schres.2006.09.027","volume":"90","author":"RR Conley","year":"2007","unstructured":"Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007;90:186\u201397.","journal-title":"Schizophr Res"},{"key":"318_CR5","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/schbul\/sbn117","volume":"34","author":"J van Os","year":"2008","unstructured":"van Os J, Rutten BP, Poulton R. Gene-environment interaction in schizophrenia: Review of epidemiological findings and future directions. Schizophr Bull. 2008;34:1066\u201382.","journal-title":"Schizophr Bull"},{"key":"318_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ijdevneu.2010.10.003","volume":"29","author":"JL Rapoport","year":"2011","unstructured":"Rapoport JL, Gogtay N. Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder. Int J Dev Neurosci. 2011;29:251\u20138.","journal-title":"Int J Dev Neurosci"},{"key":"318_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.conb.2009.05.001","volume":"19","author":"KQ Do","year":"2009","unstructured":"Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol. 2009;19:220\u201330.","journal-title":"Curr Opin Neurobiol"},{"key":"318_CR8","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.neubiorev.2010.10.008","volume":"35","author":"BK Bitanihirwe","year":"2011","unstructured":"Bitanihirwe BK, Woo TU. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2011;35:878\u201393.","journal-title":"Neurosci Biobehav Rev"},{"key":"318_CR9","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1046\/j.1460-9568.2000.00229.x","volume":"12","author":"KQ Do","year":"2000","unstructured":"Do KQ, Trabesinger AH, Kirsten-Kr\u00fcger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12:3721\u20138.","journal-title":"Eur J Neurosci"},{"key":"318_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1017\/S1461145710000805","volume":"14","author":"JW Gawryluk","year":"2011","unstructured":"Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of gluthatione, the major brain antioxidant, in post- mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol. 2011;14:123\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"key":"318_CR11","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.pnpbp.2009.06.018","volume":"33","author":"M Raffa","year":"2009","unstructured":"Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1178\u201383.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"318_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1471-244X-11-124","volume":"11","author":"M Raffa","year":"2011","unstructured":"Raffa M, Atig F, Mhalla A, Kerkeni A, Mechri A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry. 2011;11:124.","journal-title":"BMC Psychiatry"},{"key":"318_CR13","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/jnr.10439","volume":"70","author":"M Rougemont","year":"2002","unstructured":"Rougemont M, Do KQ, Castagn\u00e9 V. New model of glutathione deficit during development: Effect on lipid peroxidation in the rat brain. J Neurosci Res. 2002;70:774\u201383.","journal-title":"J Neurosci Res"},{"key":"318_CR14","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.neuroscience.2003.11.012","volume":"123","author":"V Castagn\u00e9","year":"2004","unstructured":"Castagn\u00e9 V, Cuenod M, Do KQ. An animal model with relevance to schizophrenia: sex-dependent cognitive deficits in Osteogenic Disorder-Shionogi rats induced by glutathione synthesis and dopamine uptake inhibition during development. Neuroscience. 2004;123:821\u201334.","journal-title":"Neuroscience"},{"key":"318_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.nbd.2003.09.005","volume":"15","author":"V Castagn\u00e9","year":"2004","unstructured":"Castagn\u00e9 V, Rougemont M, Cuenod M, Do KQ. Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat\u2019s development induce long-term cognitive deficit: relevance to schizophrenia. Neurobiol Dis. 2004;15:93\u2013105.","journal-title":"Neurobiol Dis"},{"key":"318_CR16","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.nbd.2006.01.003","volume":"22","author":"JH Cabungcal","year":"2006","unstructured":"Cabungcal JH, Nicolas D, Kraftsik R, Cu\u00e9nod M, Do KQ, Hornung J-P. Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: relevance to schizophrenia. Neurobiol Dis. 2006;22:624\u201337.","journal-title":"Neurobiol Dis"},{"key":"318_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.4414\/sanp.2004.01534","volume":"155","author":"KQ Do","year":"2004","unstructured":"Do KQ, Bovet P, Cuenod M. Schizophrenia: glutathione deficit as a new vulnerability factor of for the disconnectivity syndrome. Swiss Arch Neurol Psychiatry. 2004;155:375\u201385.","journal-title":"Swiss Arch Neurol Psychiatry."},{"key":"318_CR18","doi-asserted-by":"crossref","unstructured":"Lorenc-Koci E. Dysregulation of glutathione synthesis in psychiatric disorders. In studies on psychiatric disorders. Oxidative stress in applied basic research and clinical practice, 1st ed. In: Dietrich-Muszalska A, Chauhan V, Grignon S, editors, Springer: New York, NY, USA; Heidelberg, Germany; Dordrecht, The Netherlands; London, UK. 2015. p. 269\u201399.","DOI":"10.1007\/978-1-4939-0440-2_14"},{"key":"318_CR19","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/1531-8249(200010)48:4<556::AID-ANA2>3.0.CO;2-2","volume":"48","author":"GD Pearlson","year":"2000","unstructured":"Pearlson GD. Neurobiology of schizophrenia. Ann Neurol. 2000;48:556\u201366.","journal-title":"Ann Neurol"},{"key":"318_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2004.09.007","volume":"72","author":"KH Nuechterlein","year":"2004","unstructured":"Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72:29\u201339.","journal-title":"Schizophr Res"},{"key":"318_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/BF02245606","volume":"124","author":"A Schotte","year":"1996","unstructured":"Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 1996;124:57\u201373.","journal-title":"Psychopharmacology"},{"key":"318_CR22","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.pnpbp.2003.09.003","volume":"27","author":"MA Geyer","year":"2003","unstructured":"Geyer MA, Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1071\u20139.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"318_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","volume":"441","author":"S Jordan","year":"2002","unstructured":"Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137\u201340.","journal-title":"Eur J Pharmacol"},{"key":"318_CR24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1742-1241.2003.tb11397.x","volume":"57","author":"DM Taylor","year":"2003","unstructured":"Taylor DM. Aripiprazole: a review its pharmacology and clinical use. Int J Clin Prac. 2003;57:49\u201354.","journal-title":"Int J Clin Prac"},{"key":"318_CR25","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DS Shapiro","year":"2003","unstructured":"Shapiro DS, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400\u201311.","journal-title":"Neuropsychopharmacology"},{"key":"318_CR26","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0149-2918(04)90066-5","volume":"26","author":"A DeLeon","year":"2004","unstructured":"DeLeon A, Patel NC, Crismon ML. Aripiprazole, a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649\u201366.","journal-title":"Clin Ther"},{"key":"318_CR27","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1021\/acschemneuro.7b00087","volume":"8","author":"AB Casey","year":"2017","unstructured":"Casey AB, Canal CE. Classics in chemical neuroscience: aripiprazole. ACS Chem Neurosci. 2017;8:1135\u201346.","journal-title":"ACS Chem Neurosci"},{"key":"318_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2009.11.008","volume":"116","author":"SH Abbasi","year":"2010","unstructured":"Abbasi SH, Behpournia H, Ghoreshi A, Salehi B, Raznahan M, Rezazadeh SA, et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res. 2010;116:101\u20136.","journal-title":"Schizophr Res"},{"key":"318_CR29","doi-asserted-by":"crossref","unstructured":"Cho SJ, Yook K, Kim B, Choi TK, Lee KS, Y.Kim YW, et al. Mirtazapine augmentation enhances cognitive and reduced negative symptoms in schizophrenia patients treated with risperidone: A randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35: 208\u201311.","DOI":"10.1016\/j.pnpbp.2010.11.006"},{"key":"318_CR30","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.pharep.2015.04.006","volume":"67","author":"K Kami\u0144ska","year":"2015","unstructured":"Kami\u0144ska K, Rog\u00f3\u017c Z. The effect of combined treatment with risperidone and antidepressants on the MK-801-induced deficits in the social interaction test in rats. Pharmacol Rep. 2015;67:1183\u20137.","journal-title":"Pharmacol Rep"},{"key":"318_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.eurpsy.2004.06.020","volume":"19","author":"N Durany","year":"2004","unstructured":"Durany N, Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur Psychiatry. 2004;19:326\u201337.","journal-title":"Eur Psychiatry"},{"key":"318_CR32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1124\/pr.111.005108","volume":"64","author":"AE Autry","year":"2012","unstructured":"Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev. 2012;64:238\u201358.","journal-title":"Pharmacol Rev"},{"key":"318_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00213-002-1364-z","volume":"167","author":"C S\u00e1nchez","year":"2003","unstructured":"S\u00e1nchez C, Berggvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology. 2003;167:353\u201362.","journal-title":"Psychopharmacology"},{"key":"318_CR34","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.pharep.2019.04.007","volume":"71","author":"M Hereta","year":"2019","unstructured":"Hereta M, Kami\u0144ska K, Rog\u00f3\u017c Z. Co-treatment with antidepressants and aripiprazole reversed the MK-801-induced some negative symptoms of schizophrenia in rats. Pharmacol Rep. 2019;71:768\u201373.","journal-title":"Pharmacol Rep"},{"key":"318_CR35","doi-asserted-by":"publisher","unstructured":"G\u00f3rny M, Wnuk A, Kami\u0144ska A, Kami\u0144ska K, Chwatko G, Bilska-Wilkosz A, et al. Glutathione deficiency and alternations in the sulfur amino acid homeostasis during early postnatal development as potential triggering factor for schizophrenia- like behavior in adult rats. Molecules. 2019;24(23):4253. https:\/\/doi.org\/10.3390\/molecules24234253","DOI":"10.3390\/molecules24234253"},{"key":"318_CR36","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","volume":"128","author":"JC Neill","year":"2010","unstructured":"Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther. 2010;128:419\u201332.","journal-title":"Pharmacol Ther"},{"key":"318_CR37","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.2174\/1381612819666131216114240","volume":"20","author":"L Rajagopal","year":"2014","unstructured":"Rajagopal L, Massey BW, Huang M, Oyamada Y, Meltzer HY. The novel object recognition test in rodents in relative to cognitive impairment in schizophrenia. Curr Pharm Des. 2014;20:5104\u201314.","journal-title":"Curr Pharm Des"},{"key":"318_CR38","doi-asserted-by":"crossref","unstructured":"Hereta M, Kami\u0144ska K, Bia\u0142o\u0144 M, W\u0105sik A, Lorenc-Koci E, Rog\u00f3\u017c Z. Effect of combined treatment with aripiprazole and antidepressants on the MK-801-induced deficits in recognition memory in novel recognition test and on the release of monoamines in the rat frontal cortex. Behav Brain Res. 2020;September 1,393;112769.","DOI":"10.1016\/j.bbr.2020.112769"},{"key":"318_CR39","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1177\/0269881108096522","volume":"24","author":"DW Boulton","year":"2010","unstructured":"Boulton DW, Balch AH, Royzman K, Patel CG, Berman RM, Mallikaarjun S, Reevers RA. The pharmacokinetics of standard of antidepressants with aripiprazole as adjuctive therapy: studies in healthy subjects and patients with major depressive disordies. J Psychopharmacol. 2010;24:537\u201346.","journal-title":"J Psychopharmacol"},{"key":"318_CR40","doi-asserted-by":"crossref","unstructured":"Kennedy SH, Lam RW, Rotzinger S, Milev RV, Blier P, Downar J, et al. Symptomatic and functional outcomes and early prediction of response to escitalopram monotherapy and sequential adjuctive aripiprazole therapy in patients with major depressive disorder: a CAN-BINO-1-Report. J Clin Psychiatry. 2019;80:18m12202.","DOI":"10.4088\/JCP.18m12202"},{"key":"318_CR41","doi-asserted-by":"publisher","unstructured":"G\u00f3rny M, Bilska-Wilkosz A, Iciek M, Hereta M, Kami\u0144ska K, Chwatko G, et al. Alterations in the antioxidant enzymes activities in the neurodevelopmental rat model of schizophrenia induced by glutatione deficiency during early postnatal lift. Antioxidants (Basil). 2020;9:538. https:\/\/doi.org\/10.3390\/antiox9060538","DOI":"10.3390\/antiox9060538"},{"key":"318_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0197-4580(02)00015-5","volume":"24","author":"HA Bimonte","year":"2003","unstructured":"Bimonte HA, Nelson ME, Granholm AC. Age-related deficits as working memory load increases: relationships with growth factors. Neurobiol Aging. 2003;24:37\u201348.","journal-title":"Neurobiol Aging"},{"key":"318_CR43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/jnr.10440","volume":"71","author":"O Bai","year":"2003","unstructured":"Bai O, Clan-Fourney J, Bowen R, Keegan D, Li XM. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res. 2003;71:127\u201331.","journal-title":"J Neurosci Res"},{"key":"318_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.neulet.2006.03.028","volume":"402","author":"SW Park","year":"2006","unstructured":"Park SW, Lee SK, Kim JM, Yoon JS, Kim YH. Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neurosci Lett. 2006;402:5\u201329.","journal-title":"Neurosci Lett"},{"key":"318_CR45","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jpsychires.2008.05.010","volume":"43","author":"SW Park","year":"2009","unstructured":"Park SW, Lee CH, Lee JG, Lee SJ, Kim NR, Choi SM, Kim YH. Differential effects of ziprosidone and haloperidol on immobilization stress-induced mRNA expression in the hippocampus and neocortex of rats. J Psychiatr Res. 2009;43:274\u201381.","journal-title":"J Psychiatr Res"},{"key":"318_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2013.11.008","volume":"80","author":"A Luoni","year":"2014","unstructured":"Luoni A, Fumagalli F, Racagni G, Riva MA. Repeated aripiprazole treatment regulates Bdnf, Arc and Npas4 expression under basal condition as well as after an acute swim stress in the brain. Pharmanol Res. 2014;80:1\u20138.","journal-title":"Pharmanol Res."},{"key":"318_CR47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.euroneuro.2004.12.005","volume":"5","author":"G Shoval","year":"2005","unstructured":"Shoval G, Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol. 2005;5:319\u201329.","journal-title":"Eur Neuropsychopharmacol"},{"key":"318_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2007.01.025","volume":"94","author":"PF Buckley","year":"2007","unstructured":"Buckley PF, Mahadik S, Pillai A, Terry A Jr. Neurotrophins and schizophrenia. Schizophr Res. 2007;94:1\u201311.","journal-title":"Schizophr Res"},{"key":"318_CR49","doi-asserted-by":"publisher","unstructured":"Lech MA, Le\u015bkiewicz M, Kami\u0144ska K, Rog\u00f3\u017c Z, Lorenc-Koci E. Glutathione deficiency during early postnatal development causes schizophrenia-like symptoms and a reduction in BDNF levels in the cortex and hippocampus of adult Sprague-Dawley rats. Int J Mol Sci. 2021;22(12):6171. https:\/\/doi.org\/10.3390\/ijms22126171","DOI":"10.3390\/ijms22126171"},{"key":"318_CR50","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.biopsych.2020.03.016","volume":"88","author":"DO Perkins","year":"2020","unstructured":"Perkins DO, Jeffries CD, Do KQ. Potential roles of redox dysregulation in the development of schizophrenia. Biol Psychiatry. 2020;88:326\u201336.","journal-title":"Biol Psychiatry"},{"key":"318_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.schres.2014.06.021","volume":"176","author":"P Steullet","year":"2016","unstructured":"Steullet P, Cabungcal JH, Monin A, Dwir D, O\u2019Donnell P, Cuenod M, Do KQ. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a \u201ccentral hub\u201d in schizophrenia pathophysiology? Schizophr Res. 2016;176:41\u201351.","journal-title":"Schizophr Res"},{"key":"318_CR52","first-page":"223","volume":"23","author":"BK Lipska","year":"2000","unstructured":"Lipska BK, Weinberger DR. To model a psychiatric disorder in animals. Schizophrenia Reality Test Neuropsychopharmacol. 2000;23:223\u201339.","journal-title":"Schizophrenia Reality Test Neuropsychopharmacol."},{"key":"318_CR53","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S0006-8993(02)03176-1","volume":"956","author":"PC Ashe","year":"2002","unstructured":"Ashe PC, Chlan-Fourney J, Juorio AV, Li XM. Brain-derived neurotrophic factor (BDNF) mRNA in rats with neonatal ibotenic acid lesions of the ventral hippocampus. Brain Res. 2002;956:126\u201335.","journal-title":"Brain Res"},{"key":"318_CR54","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.biopsych.2003.12.011","volume":"55","author":"M Roceri","year":"2004","unstructured":"Roceri M, Cirulli F, Pessina C, Peretto P, Racagni G, Riva MA. Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions. Biol Psychiatry. 2004;55:708\u201314.","journal-title":"Biol Psychiatry"},{"key":"318_CR55","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/j.1460-9568.2004.03592.x","volume":"20","author":"F Fumagalli","year":"2004","unstructured":"Fumagalli F, Bedogni F, Perez J, Racagni G, Riva MA. Corticostriatal brain-derived neurotrophic factor dysregulation in adult rats following prenatal stress. Eur J Neurosci. 2004;20:1348\u201354.","journal-title":"Eur J Neurosci"},{"key":"318_CR56","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.pharep.2017.02.022","volume":"69","author":"Z Rog\u00f3\u017c","year":"2017","unstructured":"Rog\u00f3\u017c Z, Kami\u0144ska K, Pa\u0144czyszyn-Trzewik P, Sowa-Ku\u0107ma M. Repeated co-treatment with antidepressants and risperidone increases BDNF mRNA and protein levels in rats. Pharmacol Rep. 2017;69:885\u201393.","journal-title":"Pharmacol Rep"},{"key":"318_CR57","doi-asserted-by":"crossref","unstructured":"Alboni S, Benatti C, Capone G, Corsini D, CaggiaF, Tascedda F, et al. Time-dependent effects of escitalopram on brain derived neurotrophic factor (BDNF) and neuroplasticity related targets in the central nervous system of rats. Eur J Pharmacol. 2010;643:180\u20137.","DOI":"10.1016\/j.ejphar.2010.06.028"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00318-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-021-00318-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-021-00318-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T12:15:52Z","timestamp":1699359352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-021-00318-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1007\/s43440-021-00318-z","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"8 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}